JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Nikhil Ashokkumar Chopra as Chief Executive Officer of the company w.e.f. October 05, 2025.
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals & Pharmaceuticals has announced the re-appointment of Mr. Nikhil Ashokkumar Chopra as its Chief Executive Officer and Whole-time Director for a fresh 5-year term starting October 5, 2025, ending October 4, 2030. Mr. Chopra has been leading the company since October 2020, during which JB Pharma grew at ~16% versus the industry's 10%, and revenue nearly doubled to over ₹3,000 crore in FY23. The re-appointment is subject to shareholder approval at the upcoming annual general meeting. Under his tenure, JB Pharma moved into the top 10 in Indian cardiology and became the leader in the hypertension segment, alongside launching its second Sustainability Report.
Continuity at the top is positive for shareholders, as the existing CEO's track record shows strong revenue growth, successful acquisitions, and expansion into new therapy areas. The 5-year term provides strategic stability, though the re-appointment is still pending shareholder approval.